Katie Lynn Strong, Ph.D.
Dr. Strong is a Technical Specialist with Knowles IP Strategies, LLC. She received her Ph.D. in Organic Chemistry from Emory University in 2015 under Dr. Dennis S. Liotta, the Samuel Candler Dobbs Professor of Chemistry and an internationally acknowledged leader in academic drug discovery. In graduate school, Dr. Strong’s research focused on the development and synthesis of N-methyl-D-aspartate (NMDA) receptor subunit-selective potentiators to be used as therapeutic probes for the study of schizophrenia and cognitive enhancement. During her postdoctoral work in the laboratory of Dr. Stephen F. Traynelis at Emory University, she studied how these modulators interacted with the NMDA receptor to elicit potentiation. A patent application has been filed on this work, and papers regarding this research will be published in 2016.
During Dr. Strong’s time at Emory, she was the Assistant Managing Editor of the quarterly American Journal of Bioethics Neuroscience, a Taylor and Francis journal dedicated to publishing articles at the intersection of neuroscience and ethics. She also acted as the Managing Editor of AJOB Neuroscience’s official blog, The Neuroethics Blog, where she regularly discussed the impact of neuroscience technology on society. Dr. Strong was awarded a 2015 American Academy for the Advancement of Society (AAAS) Mass Media Fellowship, an award that was sponsored by the American Chemical Society and featured in Chemical and Engineering News (http://cen.acs.org/articles/93/i26/ACS-Sponsors-AAAS-Mass-Media.html?type=paidArticleContent).
In 2010, Dr. Strong graduated from the University of Mary Washington cum laude with a B.S. in Chemistry. For her undergraduate Honors Thesis, she developed and implemented synthetic routes for polyethylene glycol guanidinylation reagents for protecting alkylguanidines. She received an American Chemical Society Certified Degree and was awarded The American Institute of Chemist Foundation Student Award for Excellence in Chemistry in 2010.
She has co-authored a number of publications:
Strong, K.L.; Jing, Y.; Prosser, A.R.; NMDA receptor modulators: an updated patent review (2013-2014). Expert Opinion on Therapeutic Patents. 2014, 24, 1349-1346.
Santangelo, R.M.; Ogden, K.K.; Strong, K.L.; Khatri, A.; Chepiga, K.M.; Jensen, H.S.; Traynelis, S.F.; Liotta, D.C. Synthesis and Structure Activity Relationship of Tetrahydroisoquinoline-based Potentiators of GluN2C and GluN2D Containing N-Methyl-D-Aspartate Receptors. J. Med. Chem. 2013, 56, 5351-5381.
Santangelo, R.M.; Acker, T.M.; Zimmerman, S.S.; Katzman, B.M.; Strong, K.L.; Traynelis, S.F.; Liotta, D.C. Novel NMDA receptor modulators: an update. Expert Opinion on Therapeutic Patents. 2012, 22, 1337-1352.
Strong, K.L.; Epplin, M.P.; Jing, Y.; Traynelis, S.F.; Liotta, D.C. Mechanism of action of a GluN2C- and GluN2D-selective NMDA receptor positive allosteric modulator. In Allosterism in Drug Discovery, Doller, D., Ed.; Royal Society of Chemistry, submitted and accepted for publication in 2016.